CEO Marianne De Backer emphasized Vir's progress in advancing its infectious disease and oncology programs. Key milestones include initiating the ECLIPSE Phase III registrational program for hepatitis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback